Latest News and Press Releases

RhuDex® kommer att undersökas vidare i en serie laboratorietester under det brittiska läkemedelsverkets (Medicines and Healthcare products Regulatory Agency) översyn. Dessa studier kommer att...

RhuDex® will be examined in a further series of laboratory tests, under the auspices of the UK MHRA (Medicines and Healthcare products Regulatory Agency). These in-vitro studies will examine any...

Jerusalem, Israel and Lund, Sweden, September 18, 2008 - New data from the extension phase of oral laquinimod in relapsing-remitting multiple sclerosis (RRMS) demonstrated a significant reduction in...

Lund och Jerusalem, Israel, den 18 september, 2008 - Nya data från förlängningsstudien av oral laquinimod för behandling av relapserande remitterande multipel skleros (RRMS) uppvisar en signifikant...

Presentationen innefattar fas III-projekten laquinimod, en ny, immunmodulerande substans, utvecklad som en oral behandling (1 tablett om dagen) av multipel skleros, utlicensierad till Teva...

The presentation will include the Phase III projects laquinimod, a novel oral immunomodulatory drug for the treatment of Multiple Sclerosis, which is licensed to Teva Pharmaceutical Industries Ltd and...

Comments from President & CEO Sven Andréasson: "Enrolment for another clinical Phase III study for laquinimod started during the period and complete Phase II data was published in the respected...

Kommentar av VD Sven Andréasson: "Under perioden startade rekryteringen till ytterligare en klinisk fas III-studie för laquinimod och fas II kompletta data publicerades i den vetenskapliga...

Sven Andréasson har varit VD i bolaget sedan 1999 och under hans ledning har Active Biotech omvandlats från ett kombinerat vaccin- och forskningsbolag till att vara fokuserat på klinisk utveckling av...

Sven Andréasson has been the company's CEO since 1999 and under his leadership Active Biotech has been transformed from a combined vaccine and research company into a company focused on development of...